- Home
- NRSN vs KPTI Comparison
NRSN vs KPTI Comparison
Compare NRSN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- KPTI
- Stock Information
- Founded
- NRSN 2017
- KPTI 2008
- Country
- NRSN Israel
- KPTI United States
- Employees
- NRSN N/A
- KPTI N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- NRSN Health Care
- KPTI Health Care
- Exchange
- NRSN Nasdaq
- KPTI Nasdaq
- Market Cap
- NRSN 50.1M
- KPTI 44.5M
- IPO Year
- NRSN 2021
- KPTI 2013
- Fundamental
- Price
- NRSN $1.06
- KPTI $7.11
- Analyst Decision
- NRSN Buy
- KPTI Buy
- Analyst Count
- NRSN 2
- KPTI 6
- Target Price
- NRSN $14.00
- KPTI $39.80
- AVG Volume (30 Days)
- NRSN 353.2K
- KPTI 218.0K
- Earning Date
- NRSN 09-29-2025
- KPTI 08-11-2025
- Dividend Yield
- NRSN N/A
- KPTI N/A
- EPS Growth
- NRSN N/A
- KPTI N/A
- EPS
- NRSN N/A
- KPTI N/A
- Revenue
- NRSN N/A
- KPTI $137,269,000.00
- Revenue This Year
- NRSN N/A
- KPTI $3.67
- Revenue Next Year
- NRSN N/A
- KPTI $9.40
- P/E Ratio
- NRSN N/A
- KPTI N/A
- Revenue Growth
- NRSN N/A
- KPTI N/A
- 52 Week Low
- NRSN $0.68
- KPTI $3.51
- 52 Week High
- NRSN $2.60
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- NRSN 33.59
- KPTI 66.00
- Support Level
- NRSN $1.05
- KPTI $6.02
- Resistance Level
- NRSN $1.17
- KPTI $8.15
- Average True Range (ATR)
- NRSN 0.12
- KPTI 0.74
- MACD
- NRSN 0.01
- KPTI 0.24
- Stochastic Oscillator
- NRSN 10.00
- KPTI 76.42
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.